DIFFERENTIAL-EFFECTS OF QUINELORANE AND PERGOLIDE ON BEHAVIOR, BLOOD-PRESSURE, AND BODY-TEMPERATURE OF SPONTANEOUSLY HYPERTENSIVE RATS AND WISTAR-KYOTO RATS
M. Vandenbuuse, DIFFERENTIAL-EFFECTS OF QUINELORANE AND PERGOLIDE ON BEHAVIOR, BLOOD-PRESSURE, AND BODY-TEMPERATURE OF SPONTANEOUSLY HYPERTENSIVE RATS AND WISTAR-KYOTO RATS, Pharmacology, biochemistry and behavior, 50(3), 1995, pp. 389-397
The systemic administration of the dopamine agonists quinelorane or pe
rgolide to Wistar-Kyoto rats (WKY) induced a significant increase of l
ocomotor activity at higher doses. In spontaneously hypertensive rats,
these compounds induced a significant hypoactivity at low doses, but
only a modest,and late, increase in locomotor activity at higher doses
. Quinelorane was more potent than pergolide on locomotor activity. In
WKY and SHR, which had unilateral lesions of the nigrostriatal dopami
ne system, quinelorane and pergolide induced similar dose-dependent co
ntralateral turning that, in the case of pergolide, was significantly
greater in SHR than in WKY. Both quinelorane and pergolide induced yaw
ning similarly in WKY and SHR, and quinelorane was more potent than pe
rgolide. The intravenous administration of quinelorane induced an imme
diate and dose-dependent increase in blood pressure in WKY and SHR, wh
ich could be completely prevented by pretreating the rats with the dop
amine antagonist haloperidol. Pergolide similarly caused a rise in blo
od pressure in WKY and SHR, but its effect could only partially be blo
cked by haloperidol. The subcutaneous injection of quinelorane or perg
olide induced similar dose-dependent hypothermia in WKY. Pergolide als
o caused a decrease of body temperature in SHR, but quinelorane had li
ttle effect in this strain. These results show differences in the effe
cts of quinelorane and pergolide between various experimental test sit
uations and between WKY and SHR. These differences may be related to t
he involvement of dopamine receptor subtypes and to the previously des
cribed changes in central dopaminergic activity in SHR.